Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers

Purpose Low skeletal muscle mass (sarcopenia) has been reported to have an influence on survival and toxicities of chemotherapy in several solid tumors. The impact of sarcopenia on the treatment of ovarian cancers has not been determined. The present study aimed to evaluate correlation between sarco...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2017-09, Vol.80 (3), p.555-561
Main Authors: Yoshikawa, Tomoyuki, Takano, Masashi, Miyamoto, Morikazu, Yajima, Isao, Shimizu, Yukihiro, Aizawa, Yusuke, Suguchi, Yuki, Moriiwa, Miki, Aoyama, Tadashi, Soyama, Hiroaki, Goto, Tomoko, Hirata, Junko, Suzuki, Ayako, Sasa, Hidenori, Nagaoka, Isao, Tsuda, Hitoshi, Furuya, Kenichi
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers
Cancer
Cancer Research
Cancer therapies
Carboplatin
Charts
Chemotherapy
Computed tomography
Correlation analysis
Female
Humans
Medicine
Medicine & Public Health
Middle Aged
Multivariate analysis
Muscles
Musculoskeletal system
Neurotoxicity
Neutropenia
Oncology
Original Article
Ovarian cancer
Ovarian Neoplasms - drug therapy
Paclitaxel
Patients
Peripheral Nervous System Diseases - chemically induced
Peripheral neuropathy
Pharmacology/Toxicology
Psoas muscle
Psoas Muscles
Quality
Sarcopenia
Skeletal muscle
Solid tumors
Spine
Thrombocytopenia
Toxicity
Tumors
Vertebrae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Low skeletal muscle mass (sarcopenia) has been reported to have an influence on survival and toxicities of chemotherapy in several solid tumors. The impact of sarcopenia on the treatment of ovarian cancers has not been determined. The present study aimed to evaluate correlation between sarcopenia and toxicities of chemotherapy in ovarian cancers. Methods Medical charts of the ovarian cancer patients that received chemotherapy with paclitaxel and carboplatin at our hospital between 2010 and 2015 were retrospectively reviewed. Muscle areas of bilateral psoas major muscles at the fifth lumbar vertebra were measured using images obtained by computed tomography. The volume of muscle and clinicopathological factors were evaluated for toxicities of chemotherapy. The protocol of the present study was approved by the institutional review board of our institution. Results A total of 76 patients with ovarian cancers were identified, and enrolled in the present study. Median psoas index (PI, the psoas muscle major cross-sectional area divided by the height squared) was 583 mm 2 /m 2 (range 326–999). The patients with low PI developed peripheral neuropathy more frequently compared with those with high PI (32 vs. 11%; P  = 0.047). PI value was not associated with other toxicities such as neutropenia and thrombocytopenia. PI value was associated with grade 2 or higher peripheral neuropathy in univariate analysis (OR = 3.92; 95% CI 1.21–15.32; P  = 0.02) and multivariate analysis (OR = 3.93; 95% CI 1.17–15.87; P  = 0.03). Conclusions PI value was significantly associated with peripheral neuropathy induced by combination therapy with paclitaxel and carboplatin in ovarian cancer patients. Although further studies are needed to confirm the results, the volume of skeletal muscle mass could be a potential biomarker to predict toxicities in ovarian cancer patients.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-017-3395-5